LONDON (Alliance News) - Collagen Solutions PLC Tuesday said it is partnering up with University College London and Oxford MEStar Ltd to develop a scaffold that can be used to treat large osteochondral defect repairs, through a grant awarded by Arthritis Research UK.
Collagen, which develops medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, said the scaffold will provide a one-step surgical procedure for the treatment of osteochondral injuries, which refers to repetitive trauma within a joint such as the knee or elbow.
Osteochondral defects can lead to osteoarthritis, but the scaffold would enable a pain free, more active lifestyle for patients, Collagen said.
Oxford MEStar is a company specialising in translational and regenerative medicine.
"Our relationship with UCL has already led to the licensing of novel collagen material from the laboratories of Professor Brown. This new grant widens our collaboration with the university and will lead to the development of another collagen based, high value added product which fits in with our strategy of releasing the embedded functionality of our medical grade collagen through the development and commercialisation of high value added novel products," Chief Executive Stewart White said in a statement.
Shares in Collagen were trading up 4.6% at 10.20 pence Tuesday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
